PLUS1
37.54
1.78 (4.98%)
1.78 (4.98%)
Upgrade to Real-Time
Afterhours
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| uniQure NV | QURE | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 1.78 | 4.98% | 37.54 | 17:15:00 |
| Close Price | Low Price | High Price | Open Price | Previous Close |
|---|---|---|---|---|
| 37.54 | 36.00 | 38.18 | 36.11 | 35.76 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 37.20 | 37.75 | 0.55 | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 5,659 | 424,934 | $ 37.52 | $ 15,944,528 | 419,032 | 34.38 - 76.6869 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:40:01 | 1 | $ 37.31 | USD |
uniQure NV Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 1.67B | 44.45M | 39.76M | $ 7.28M | $ - | -3.12 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
uniQure NV News
| Date | Time | Source | News Article |
|---|---|---|---|
| 10/16/2020 | 16:10 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 10/13/2020 | 07:05 | GlobeNewswire Inc. | uniQure Announces Enrollment of Next Two Patients in Phase.. |
| 9/30/2020 | 07:05 | GlobeNewswire Inc. | uniQure to Participate in Multiple Upcoming Industry.. |
| 9/25/2020 | 07:05 | GlobeNewswire Inc. | uniQure Announces Recommendations from Data Safety.. |
| 9/22/2020 | 09:55 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 9/22/2020 | 09:48 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 9/18/2020 | 13:41 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical QURE Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 36.89 | 38.18 | 34.38 | 35.88 | 307,623 | 0.65 | 1.76% |
| 1 Month | 40.85 | 41.47 | 34.38 | 37.06 | 322,413 | -3.31 | -8.1% |
| 3 Months | 39.81 | 43.3894 | 34.38 | 39.39 | 397,798 | -2.27 | -5.7% |
| 6 Months | 55.82 | 71.45 | 34.38 | 48.79 | 492,813 | -18.28 | -32.75% |
| 1 Year | 43.11 | 76.6869 | 34.38 | 53.47 | 480,996 | -5.57 | -12.92% |
| 3 Years | 12.15 | 82.49 | 11.55 | 44.20 | 506,112 | 25.39 | 208.97% |
| 5 Years | 18.78 | 82.49 | 4.72 | 36.19 | 400,723 | 18.76 | 99.89% |
uniQure NV Description
| uniQure NV is a gene therapy company. It develops treatment and platform for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers-Squibb for cardiovascular diseases. |
